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Alopecia areata is an autoimmune disease targeted at
hair follicles with in¢ltrated T lymphocytes probably
playing an important role in the pathogenesis. It was
reported in 1985 that mechlorethamine was e¡ective on
alopecia areata patients. This has never been con¢rmed
since. The aims of the study were to investigate the
e¡ects of mechlorethamine on balding C3H/HeJ mice
a¡ected with an alopecia-areata-like disease and to study
the underlying mechanisms. Mice were treated on half
of the dorsal skin with mechlorethamine and the con-
tralateral side was treated with the vehicle ointment.
After 10 wk of mechlorethamine therapy, a full pelage
of hair covered the treated side in all the mice and was
maintained during the study, whereas the vehicle-trea-
ted sides showed either no change or continued hair
loss. Immunohistochemistry revealed that in¢ltrated
CD4þ and CD8þ lymphocytes were eliminated from
the treated side. In vitro cell viability assay showed that
lymphocytes were much more sensitive to the cytotoxic
e¡ects of mechlorethamine than skin and hair follicular
cells. RNase protection assay and real-time reverse tran-
scription polymerase chain reaction showed that tumor
necrosis factor a/b, interleukin-12, and interferon-c
were inhibited by mechlorethamine upon successful
treatment. Our ¢ndings support that mechlorethamine
restores follicular activity by selectively targeting in¢l-
trated lymphocytes in vivo in alopecia-areata-a¡ected
mice. Key words: C3H/HeJ mice/cytokines/hair growth/
topical therapy. J Invest Dermatol 120:400 ^406, 2003
A
lopecia areata (AA) is a common in£ammatory dis-
ease of the hair follicle that a¡ects 1.7% of the popu-
lation and results in patchy to complete hair loss
(Safavi et al, 1995). It is widely regarded as an auto-
immune disease (McDonagh and Messenger, 1996;
McElwee et al, 1999a; Gilhar et al, 2001), but the precise cause of
the disease is unknown. Perifollicular and intrafollicular in£am-
matory cell in¢ltrates are characteristic of AA. The in¢ltrating
cells are mainly activated T lymphocytes with an admixture of
macrophages and Langerhans cells that appear to preferentially
a¡ect anagen stage hair bulbs within active lesions of AA (Perret
et al, 1984;Todes-Taylor et al, 1984). Awide range of treatments are
used for AA, including contact sensitizers, immunomodulators,
and biologic response modi¢ers (Ho¡mann and Happle, 1996;
Shapiro and Price, 1998), but their e⁄cacy is variable and unpre-
dictable and many are associated with signi¢cant untoward side-
e¡ects. The treatment of AA with topical mechlorethamine
(nitrogen mustard) was reported to be e¡ective by Arrazola et al
in 1985, but there have been no further studies on this agent up to
now. It is necessary to investigate the e⁄cacy and safety of this
treatment in an AA-a¡ected animal model prior to conducting
more extensive human clinical trials.
The C3H/HeJ inbred mouse strain develops a spontaneous
di¡use, nonscarring alopecia with clinical and pathologic features
similar to human AA (Sundberg et al, 1994; Sundberg and King,
1996). The incidence of hair loss can be as high as 20% in some
colonies of mice aged 18 mo or older. Recently, this hair loss phe-
notype has been induced by grafting full-thickness AA-a¡ected
skin onto histocompatible mice (McElwee et al, 1999b). This
inducible C3H/HeJ mouse model provides a convenient model
system for which new forms of treatment can be developed,
tested, and analyzed from a mechanistic point of view.We and
other investigators have shown that contact immunotherapy
using diphenylcyclopropenone and squaric acid dibutylester,
immunosuppressive drug FK506, and anthralin stimulates hair
regrowth in AA-a¡ected mice (Freyschmidt-Paul et al, 1999;
2001; Shapiro et al, 1999). In this report we describe the e⁄cacy
and possible mechanisms of mechlorethamine on hair restoration
in C3H/HeJ mice a¡ected byAA-like disease.
Mechlorethamine was the ¢rst alkylating agent to be tested for
human malignancies and is still being used for the treatment of a
variety of cancers including leukemia, lymphoma, and other solid
tumors (Engert et al, 1999; Tesch et al, 2001). The topical form is
widely used in the treatment of cutaneous T cell lymphoma
(Ramsay et al, 1995; Duvic et al, 1996; Esteve et al, 1999) and
Langerhans cell histiocytosis (Hoeger et al, 2000). Mechloretha-
mine-induced DNA damage has been the primary mechanism
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responsible for its anticancer e¡ects. In AA, we propose that me-
chlorethamine may selectively target the in¢ltrated lymphocytes
thereby leading to restoration of hair follicle activity. On the
other hand, a number of in£ammatory cytokines have been indi-
cated in the pathogenesis of AA including interleukin-1b (IL-1b),
tumor necrosis factor a (TNF-a), and interferon-g (IFN-g) (Hap-
ple and Ho¡mann, 1995; Philpott et al, 1996; Carroll et al, 1997). It
is possible that mechlorethamine may inhibit the production of
these cytokines in AA. This study was designed to explore both
the cellular and molecular targets responsible for mechloretha-
mine’s ability to reverse the autoimmune-arrested hair follicle
activity in AA-a¡ected C3H/HeJ mice.
MATERIALS AND METHODS
Mice AAwas induced by grafting full-thickness AA-a¡ected mouse skin
onto the normal C3H/HeJ mice (McElwee et al, 1999b). Mice were grafted
at the Jackson Laboratory and shipped toVancouver General Hospital. The
grafted mice were housed individually in environmentally controlled cages
with an alternating 12 h daynight cycle. Hair loss typically began at
around 8 wk after grafting and ranged from large bald areas on the £anks
and heads to almost complete loss of head and body hair. Twenty-four
grafted C3H/HeJ mice (all females, mean age 8 mo, average 8 wk after
grafting) were used for this study. Eight age-matched normal C3H/HeJ
(all females) were used as controls. The skin grafting procedure was
approved by the Jackson Laboratory Animal Care and Use Committee
and this study was approved by the University of British Columbia
Animal Care Committee.
Drug treatment and hair growth grading Topical mechlorethamine
was prepared as a 0.02% mechlorethamine ointment in Aquaphor. The
vehicle control (Aquaphor) was identical except for the absence of
mechlorethamine. The mice were treated on half of their dorsal skin by
even application of mechlorethamine; the contralateral side was treated
identically with the vehicle ointment. Topical treatment was applied for
¢ve consecutive days each week for a total of 10 wk. During treatment
mice were weighed and photographed weekly.
Hair growth was measured weekly and semiquantitatively by assigning
hair density/quality and hair surface coverage. For each side, the percentage
of hair surface coverage was estimated. The quality and density of the hair
were assessed and graded on a four-point scale (grade 0, no hair; grade 1,
stubble and short hairs; grade 2, sparse and intermediate length hairs; grade
3, normal length and density hairs). Hair score was independently
estimated by three investigators. The quality/density grade for each area
multiplied by the percentage areas of hair coverage were added together
to give the total hair growth index for each side of the animals.
Hair Growth Index ¼
X3
Hair quality¼0
ðHair qualityÞ
ðPercentage of half dorsal surfaceÞ
For example, if 25% of a half dorsal surface is covered with grade 1 hair
and the remaining portion (75%) with grade 2 hair, the hair growth index
for this side will be 175 (125þ2 75¼175). The minimum would be 0
(no hair) and a maximum score of 300 (100% normal hair and full pelage)
would be for a full half dorsal surface.
Tissue collection One day after the last treatment at the end of study
(10 wk), mice were asphyxiated with CO2 and necropsied. Full-thickness
skin biopsies were excised as thin strips from the dorsal surface of each
mouse from both mechlorethamine-treated and control sides. Skin
samples were snap frozen in liquid nitrogen and kept at 801C for RNA
extraction. For immunohistochemistry, skin biopsies were embedded in
Tissue-Tek OCT compound (Sakura Finetek, Torrance, CA), snap frozen
in liquid nitrogen, and stored at 801C.
Immunohistochemistry All antibodies were purchased from BD
PharMingen (San Diego, CA) and processed using the supplier’s
protocols. Serial 6 mm sections of skin were cut on a cryostat. After
removing the frozen mounting media with phosphate-bu¡ered saline
(PBS), endogenous peroxidase activity was quenched with 0.03% H2O2
solution in PBS. Sections were then incubated with primary antibodies
[rat antimouse CD4 (H129.19) or rat antimouse CD8a (53^6.7)] overnight
at 41C. Rat IgG2a (R35-95) and PBS were used as isotype and negative
controls, respectively. After washing with PBS, sections were incubated
with biotinylated antirat IgG1/2a secondary antibody (G28-5) at 371C for
1 h and then with avidinbiotinhorseradish peroxidase complex (Vector
Laboratories, Burlingame, CA) for another hour at 371C. The reaction was
visualized by immersing sections in diaminobenzidine solution (Sigma, St.
Louis, MO) for around 20 min and counterstained with hematoxylin.
Cell culture, cell viability, and proliferation assay Human epidermal
keratinocytes and dermal ¢broblast cells were cultured from neonatal
forskin and used at passages 4^6 using Gibco’s keratinocyte growth
medium and Dulbecco’s minimum essential medium (DMEM)
containing 10% fetal bovine serum (FBS), respectively (Invitrogen,
Carlsbad, CA). Mouse dermal ¢broblasts were cultured in DMEM with
10% FBS and used at passages 4^5. Follicular keratinocytes and dermal
papilla ¢broblast cells were cultured from the adult scalp hair follicles as
described previously (Warren et al, 1991; Reynolds et al, 1993). Hair follicle
specimens were obtained from male adults who were undergoing hair
transplantation under a protocol approved by the University of British
Columbia Clinical Research Board. The follicular epithelium and dermal
papilla were microdissected and cultured separately. Follicular keratinocytes
were seeded in keratinocyte medium as above and dermal papilla ¢broblast
cells were cultured in M199 (Invitrogen) medium containing 20% FBS.
Upon passage, dermal papilla cells were cultured in M199 medium
containing 10% FBS. The follicular cells were used at passages 3^4. Jurkat
lymphoma cells, mouse spleen lymphocytes, and human peripheral blood
mononuclear cells were cultured in RPMI 1640 (Invitrogen) plus 10% FBS.
The primary lymphocytes were stimulated by 5 mg per ml of ConA
(mouse) or 5 mg per ml of phytohemagglutinin (human) (Amersham-
Pharmacia, Piscataway, NJ). The cells were treated with di¡erent doses of
mechlorethamine. For cell survival assay, 3-[4,5-dimethylthiazol-2-yl]-2,5-
diphenyl tetrazolium bromide (MTT) was added to the culture for 4 h
after 44 h of treatment and the optical density at 590 nm was used to
measure the cell viability. For cell proliferation assay, cells were treated
with mechlorethamine for a total of 48 h and 3H-thymidine (1 mCi per
ml) (Amersham-Pharmacia) was added to the culture 16 h before
harvesting. Then the cells were lyzed and harvested onto ¢brotic ¢lter
paper and unincorporated 3H-thymidine was washed o¡ using a cell
harvestor. The incorporation of 3H-thymidine into the cells was measured
by scintillation counting.
RNA extraction and RNase protection assay (RPA) Total RNA
was prepared from whole skin using TrizolTM solution (Invitrogen) and a
polytron homogenizer. Yield and purity were assessed by ultraviolet
spectrophotometry and gel electrophoresis. RPA were performed using
PharMingen’s RiboQuants Multi-Probe Ribonuclease Protection Assay
System (BD PharMingen). The following gene sequences were included
in the templates: IL-1a, IL-1b, IL-1 receptor antagonist (IL-1Ra), IL-10,
IL-12, IL-18, TNF-a, TNF-b, IFN-g, macrophage migration inhibitory
factor 1 (MIF-1), and two housekeeping genes, L32 and glyceraldehyde-3-
phosphate dehydrogenase (GAPDH). Total RNA 15 mg was used for each
RPA. Probe synthesis, hybridization, and RNase treatment were
performed by following the manufacturer’s instructions. 32P[d-UTP] was
used to label the probe (Amersham-Pharmacia). The ‘‘RNase-protected’’
fragments were resolved on 6% polyacrylamide gel containing 4 M urea
and the dried gel was exposed to X-ray ¢lm for various times. The signals
were detected by autoradiography.
Quanti¢cation of cytokine expression by real-time polymerase
chain reaction (PCR) The expression of cytokine transcript in skin
biopsies was also analyzed by real-time reverse transcription PCR (RT-
PCR) using a LightCycler (Roche Diagnostics, Indianapolis, IN). One
microgram of total RNA was used for cDNA synthesis by random
hexamer and SuperScript IIþ reverse transcriptase following the
manufacturer’s instruction (Invitrogen). The resulting cDNA (initial
volume of 20 ml) reaction was diluted with H2O to 200 ml and used
as templates for PCR. The primer sequences designed for PCR
ampli¢cation are as follows: IL-1b, forward 50 -CAACCAACAAGTGA-
TATTCTCCATG-30, reverse 50 -GATCCACACTCTCCAGCT GCA-30;
IL-1Ra, forward 50 -CCTCGGGATGGAAATCTGCT-30, reverse 50 -CCA-
GATTCTGAAGGCTTGCAT-30; IL-10, forward 50 -GGTTGCCAAGC-
CTTATC GGA-30, reverse 50 -ACCTGCTCCACTGCCTTGCT-30; IL-12,
forward 50 -GGAAGC ACGGCAGCAGAATA-30, reverse 50 -AACTTGA-
GGGAGAAGTAGGAATGG-30; TNF-a, forward 50 -ATCTTCTCAAAA-
TTCGAGTGACAA-30, reverse 50 -TGGGAG TAGACAAGGTACAA-
CCC-30; IFN-g, forward 50 -TCAAGTGGCATAGATGTGGAAGAA-30,
reverse 50 -TGGCTCTGCAGGATTTTCATG-30; and b-actin, forward 50 -
AGAGGGAAATCGTGCGTGAC-30, reverse 50 -CAATAGTGATGACCT-
GGCCGT-30. The PCR was carried out in a ¢nal volume of 20 ml
containing 1 ml of the above diluted cDNA reaction, 200 nM primer, 1
unit of PlatinumsTaq DNA polymerase (Invitrogen), 200 mM dNTPs,
3.75 mM MgCl2, 250 mg of bovine serum albumin, and 1.5 ml of SYBR
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Green I (Sigma). Duplicate reactions were performed for each sample.
Regular RT-PCR was performed for each candidate gene and gel
electrophoresis was used to con¢rm the correct size and speci¢city of
the ampli¢ed signals. Thermal cycling conditions were 5 s at 951C, 5 s at
551C^601C (depending on the primer’sTm), and 20 s at 721C for a total of
up to 35 cycles. Fluorescence values representing the amount of ampli¢ed
product in the PCR were automatically recorded during every cycle. A
crossing point, which always occurs during the exponential phase of
ampli¢cation for each particular reaction, is used to quantitate the relative
amount of RNA present in the initial reaction and is de¢ned as the
threshold cycle (Ct) (Gibson et al, 1996; Bustin, 2000). The more templates
that are present at the beginning of the reaction, the fewer cycle numbers it
takes to reach the crossing point. Thus, the Ct value is inversely
proportional to the log of the initial copy number. Then the Ct value of
each cytokine was normalized to that of b-actin ampli¢ed from the same
sample and used for relative quantitation. The threshold cycle number
di¡erence (DCt) between control and mechlorethamine-treated sides of
the same mouse was obtained by subtracting Ctcontrol from Cttreated.
When DCt was positive, the value of 2
DCt was used as fold increase by
mechlorethamine. With negative DCt, the product of ^2
^DCt was used as
fold inhibition by mechlorethamine.
RESULTS
Mechlorethamine restores follicular activity in AA-a¡ected
mice The baseline hair index before the treatment was the
same on both sides (Fig 1). After 10 wk of treatment, the average
hair regrowth index was signi¢cantly higher on the treated sides
than the control sides [28379 vs 138729 (mean7SD); po0.001,
Wilcoxon signed-ranks test]. On the treated sides, signi¢cant hair
regrowth was observed by the fourth to ¢fth week of treatment
and was maintained in all the animals throughout the study
(Fig 1). By week 10, a full pelage of hair was present on the
treated sides in all the mice. The control sides on 21 out of 24
mice showed either continued hair loss or no change in hair
density and length. Three other mice showed spontaneous hair
regrowth on the control sides at the tenth week, but the hair
indices were still much lower than those of the treated sides
(data not shown). Over the course of the study, a total of four
mice exhibited various degrees of spontaneous hair regrowth on
the control side at di¡erent time points and then hair was lost
usually within 1^2 wk thereafter (data not shown). The
photographs of a representative mouse are shown in Fig 2. As a
control, eight normal C3H/HeJ mice were shaved on the back
and then treated the same way as AA-a¡ected mice. No
di¡erence between mechlorethamine-treated and control sides
in hair regrowth was observed after a similar course of
mechlorethamine treatment (Fig 2G, H). In all the normal
mice, complete hair regrowth was noticed from 8 to 10 wk after
the onset of the treatment from both sides.Throughout the study,
all mice were healthy and maintained constant body weights. In
mechlorethamine-treated skin, no dermatitis, erythema, or
pigmentary changes were observed. Therapy was terminated
after 10 wk of topical mechlorethamine. Sixteen AA-a¡ected
mice were sacri¢ced for tissue processing and the remaining
eight AA-a¡ected mice were left untreated for another 3 mo.
The unilateral hair regrowth was still maintained in all eight
mice even 3 mo after the termination of mechlorethamine
therapy although minimal to moderate hair regrowth was also
noticed from the control sides in six of eight mice (data not
shown).
Mechlorethamine targets in¢ltrated lymphocytes in AA-
a¡ected mice Topical mechlorethamine is used widely in the
treatment of cutaneous T cell lymphoma. In AA therapy,
mechlorethamine may target the in¢ltrated lymphocytes in AA-
a¡ected skin and therefore restore the follicular activity. In this
case, it should selectively suppress the in¢ltrated lymphocytes
and leave the follicular cells unhindered in AA-a¡ected skin.
Using immunohistochemistry, both CD4þ and CD8þ
lymphocytes were eliminated by mechlorethamine treatment in
all 12 mice examined (Fig 3C, D, G, H). Both CD4þ and
CD8þ cells were easily observed from the control sides where
the in¢ltrates were mainly perifollicular and intrafollicular (Fig
3A, B, E, F).
To further examine the selective activity of mechlorethamine
on lymphocytes in vitro, di¡erent cell types were treated with
various concentrations of mechlorethamine. Mechlorethamine’s
cytotoxicity and proliferation inhibitory e¡ects were determined
and compared. As shown in Fig 4, activated primary mouse and
human T lymphocytes and a lymphoma T cell line (Jurkat) cells
were all much more susceptible to mechlorethamine’s cytotoxic
and proliferation inhibitory e¡ects than all other native skin
cells including follicular and epidermal keratinocytes as well as
dermal and follicular dermal papillae ¢broblasts.
TNF-a/b, IFN-c, and IL-12 are inhibited by mechlorethamine
in AA-a¡ected mouse skin In skin, a large number of
cytokines are produced under both normal and pathologic
conditions and play important roles in the pathogenesis of
in£ammatory skin diseases. As the follicular activity in all AA-
a¡ected mice returned to a near normal level on all the
mechlorethamine-treated sides whereas the control sides
remained bald, the underlying cellular and molecular changes
mediated by mechlorethamine must occur locally within the
treated skin. Cytokines including IL-1b, TNF-a, IFN-g, and IL-
1Ra have been indicated in the pathogenesis of AA (Happle and
Ho¡mann, 1995; Philpott et al, 1996; Carroll et al, 1997).To explore
the possible molecular mechanisms of mechlorethamine’s
therapeutic e¡ects on hair restoration in AA-a¡ected C3H/HeJ
mice, RPA was performed using a template set for various
cytokines on the skin biopsies of mechlorethamine-treated and
control sides. The expression of TNF-a/b and IL-12 was
consistently and noticeably inhibited on the treated sides in all
12 mice examined (Fig 5). Expression of IFN-g was detectable
(weakly) from all the control sides, but absent from the treated
sides (data not shown). IL-18, MIF-1, and IL-1Ra were three
abundant cytokines expressed in mouse skin, but did not
exhibit any di¡erences between the two sides (data not shown).
The other weakly expressed cytokines in the mouse skin were
IL-10 and IL-1a/b and no di¡erences between the two sides
were observed (data not shown).
Figure1. Mechlorethamine increased hair indices in C3H/HeJ
mice. Each data point represents the average hair indices of 24 mice over
10 wk of mechlorethamine treatment. There was no baseline di¡erence in
hair indices between the two sides before treatment. Signi¢cant increase
in hair indices was observed on the treated sides after the fourth week of
mechlorethamine treatment, whereas the control-vehicle-treated sides
remained unchanged over the course of the experiment. Error bars
represent SD.
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Using a more sensitive assay, the real-time RT-PCR, we
further compared the relative expression of six cytokines
between mechlorethamine-treated and control mouse skin. As
observed by RPA, TNF-a, IFN-g, and IL-12 demonstrated
decreased expression by mechlorethamine therapy (Fig 6). Other
cytokines including IL-1b, IL-10, and IL-1Ra showed no
signi¢cant di¡erence between the two sides (Fig 6). The data
obtained by real-time RT-PCR were consistent with those of
the RPA (Figs 5, 6).
DISCUSSION
None of the current therapies for AA are consistent in terms of
e⁄cacy. A previous clinical trial using mechlorethamine on AA
patients reported some success (Arrazola et al, 1985). This study
con¢rms the e⁄cacy of topical mechlorethamine in restoring
hair follicle activity to normal in C3H/HeJ mice with AA-like
hair loss. On the treated sides, complete or nearly complete hair
coverage developed in all the mice tested, whereas the majority of
the control sides either remained unchanged or showed further
hair loss. Mechlorethamine thus appears to be the most e¡ective
treatment among the drugs tested to date on AA-a¡ected mice.
The e¡ects of mechlorethamine on normal C3H/HeJ mice were
also tested and no indication of hair stimulatory e¡ects was ob-
served after a similar course of mechlorethamine treatment (Fig
2G, H), indicating that mechlorethamine’s therapeutic e¡ects on
hair regrowth are speci¢c for AA-a¡ected mice. Our results con-
¢rm the utility of the C3H/HeJ mouse model with an AA-like
disease for exploring the comparative molecular mechanisms of
topical therapeutic agents for AA. Based on this animal work,
we have also conducted a small controlled half-head human
study and found that one in ¢ve of AA patients with 50%^99%
scalp involvement showed a signi¢cant unilateral response to
topical mechlorethamine therapy after 16 wk (Bernardo et al,
in press).
The presence of perifollicular and intrafollicular in£ammatory
in¢ltrates represents one of the best-characterized histologic signs
Figure 2. A female C3H/HeJ mouse was successfully treated unilaterally with mechlorethamine. There was no di¡erence in hair density 1 wk
after the treatment (A, C, E). After 6 wk, the mechlorethamine-treated right side (B, F) showed normal hair density, whereas the vehicle-treated left side (B,
D) showed more hair loss than at baseline. A normal mouse showed no di¡erence in hair growth between mechlorethamine-treated right side and control-
vehicle-treated left side either before (G) or after 6 wk of treatment (H). Hair regrowth was present on both sides after 6 wk of treatment (H).
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of AA lesions. The pathogenic roles of activated CD4þ and
CD8þ lymphocytes have been directly demonstrated by cell
transfer experiments (Becker et al, 1996; McElwee et al, 1996;
1999c; Gilhar et al, 1998). A direct mechanism of mechloretha-
mine’s therapeutic e¡ects on AA can be due to its selective cyto-
toxicity. Our observation that both CD4þ and CD8þ
lymphocytes were eliminated from the mechlorethamine-treated
sides (Fig 3) strongly suggests that topical mechlorethamine ther-
apy might selectively target the in¢ltrating lymphocytes in vivo in
AA-a¡ected skin to restore autoimmune-arrested hair follicle ac-
tivity. This is further supported by the fact that in vitroT lympho-
cytes were more susceptible to mechlorethamine’s cytotoxic e¡ect
than other skin cells (Fig 4).
The biochemical basis of a di¡erential response to mechlor-
ethamine in di¡erent cell types is currently unknown. The ther-
apeutic e¡ects of mechlorethamine are due to apoptotic cell death
caused by DNA damage through production of free oxygen radi-
cals (Holl et al, 2000; Letourneau et al, 2000; Moller et al, 2000).
Underlying molecular mechanisms have not been extensively
studied. The DNA-dependent protein kinase complex (DNA-
PK), which is critical for DNA double strand break repair, has
been shown to correlate to both clinical and in vitro sensitivity of
leukemia cells to mechlorethamine (Muller et al, 1998; 2000).We
have compared the expression of DNA-PK protein in di¡erent
cell types and no di¡erence at the basal level of DNA-PK was
found (data not shown), indicating that the di¡erential response
between T cells and other cell types to mechlorethamine is due
to a mechanism other than DNA-PK. The underlying molecular
basis needs to be further investigated.
The molecular mechanism of mechlorethamine on hair
growth is currently unknown. At the molecular level, therapeutic
e¡ects of mechlorethamine might result from inhibition of cer-
tain disease-causing pro-in£ammatory cytokines within the skin.
By comparing the cytokine expression pro¢le between the me-
chlorethamine-treated and control sides, we have found that
TNF-a/b, IL-12, and IFN-g were consistently inhibited by me-
chlorethamine. Increased expression of these cytokines has been
shown to be associated with the pathogenesis of various autoim-
mune conditions and some of them have been served as thera-
peutic target molecules (Cork et al, 1995; Joosten et al, 1996;
Cope, 1998; Firestein, 1998; Feldmann and Maini, 2001; Kassiotis
and Kollias, 2001).We have recently compared cytokine expres-
sion pro¢les between AA-a¡ected and normal C3H/HeJ mouse
skin, and found that all the above four cytokines were more
abundantly expressed in AA-a¡ected mice. It is not clear whether
decreased expression of TNF-a/b, IL-12, and IFN-g is responsi-
ble for reversing the autoimmune-arrested follicular activity in
AA or is just secondary to the loss of the T cell in¢ltrates. Both
IL-12 and IFN-g are mainlyTcell derived, thus it is plausible that
their reduced expression might be mainly due to the lack of Tcell
in¢ltrates. TNF-a can be produced by various cell types and the
lack of T cells in the skin cannot be the sole reason for the re-
duced expression of TNF-a. In another study, we have found that
decreased expression of TNF-a/b correlated with anthralin’s e⁄-
cacy in stimulating hair regrowth in this AA model without af-
fecting the total number of T cell in¢ltrates in the mouse skin. It
would be interesting to determine whether any of these cyto-
kines play a direct role in therapeutically induced hair regrowth
in AA-a¡ected animal models.
In conclusion, mechlorethamine can fully restore the activity
of autoimmune-arrested follicles in C3H/HeJ mice and can be a
promising therapeutic reagent for AA. It appears that speci¢cally
targeting activated T lymphocytes in a¡ected skin may downre-
gulate IL-12, TNF-a/b, and IFN-g, and this may be responsible
for mechlorethamine’s therapeutic e¡ects in C3H/HeJ mice with
AA-like disease. At a molecular level, genes responsible for hair
follicle activity and cutaneous immune function in AA patients
are similar to those in AA-a¡ected C3H/HeJ mice. Studying the
molecular mechanisms regulating hair follicle activity in animal
models is of great bene¢t in the rational design of more re¢ned
therapeutic modalities for patients. In addition, it has been di⁄-
cult to obtain truly relevant in vivo data of therapeutic actions on
other diseases, due to the inaccessibility and invisibility of the
a¡ected tissues in other autoimmune diseases and variations
Figure 3. Immunohistochemistry of C3H/HeJ mouse skin with CD4+ (A, B, C, D) and CD8+ (E, F, G, H) antibodies on the control (A, B, E,
F) and mechlorethamine-treated (C, D, G, H) sides. Both CD4+ and CD8+ subpopulations of lymphocytes were depleted on the treated sides from
perifollicular and intrafollicular areas (compareA, B with C, D; E, F with G, H). Scale bars: 25 mM.
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between individuals. Such a topically and unilaterally treated AA
animal model can be a useful system for studying therapeutic
e¡ects of drugs in vivo at molecular levels in general.
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